Geneuro Reports Postive Phase IIa Data for MS Drug
By Nuala Moran
Monday, November 4, 2013
Geneuro SA announced positive results from the Phase IIa trial of GNbAC1, a first-in-class monoclonal antibody targeting an endogenous retroviral protein identified as involved in the onset and development of multiple sclerosis, with the drug showing a very good safety profile and nine of 10 patients having stable disease, as assessed by MRI brain scans.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.